1. Home
  2. TPH vs IBRX Comparison

TPH vs IBRX Comparison

Compare TPH & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TPH
  • IBRX
  • Stock Information
  • Founded
  • TPH 2009
  • IBRX 2014
  • Country
  • TPH United States
  • IBRX United States
  • Employees
  • TPH N/A
  • IBRX N/A
  • Industry
  • TPH Homebuilding
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TPH Consumer Discretionary
  • IBRX Health Care
  • Exchange
  • TPH Nasdaq
  • IBRX Nasdaq
  • Market Cap
  • TPH 2.9B
  • IBRX 2.4B
  • IPO Year
  • TPH N/A
  • IBRX N/A
  • Fundamental
  • Price
  • TPH $29.40
  • IBRX $2.67
  • Analyst Decision
  • TPH Strong Buy
  • IBRX Strong Buy
  • Analyst Count
  • TPH 5
  • IBRX 5
  • Target Price
  • TPH $42.80
  • IBRX $11.40
  • AVG Volume (30 Days)
  • TPH 1.0M
  • IBRX 11.6M
  • Earning Date
  • TPH 07-24-2025
  • IBRX 05-12-2025
  • Dividend Yield
  • TPH N/A
  • IBRX N/A
  • EPS Growth
  • TPH 20.35
  • IBRX N/A
  • EPS
  • TPH 4.51
  • IBRX N/A
  • Revenue
  • TPH $4,294,395,999.00
  • IBRX $31,222,000.00
  • Revenue This Year
  • TPH N/A
  • IBRX $579.01
  • Revenue Next Year
  • TPH $7.76
  • IBRX $173.61
  • P/E Ratio
  • TPH $6.53
  • IBRX N/A
  • Revenue Growth
  • TPH 10.82
  • IBRX 10238.41
  • 52 Week Low
  • TPH $27.90
  • IBRX $1.83
  • 52 Week High
  • TPH $47.78
  • IBRX $7.63
  • Technical
  • Relative Strength Index (RSI)
  • TPH 39.97
  • IBRX 53.37
  • Support Level
  • TPH $29.44
  • IBRX $2.43
  • Resistance Level
  • TPH $30.66
  • IBRX $2.79
  • Average True Range (ATR)
  • TPH 0.70
  • IBRX 0.22
  • MACD
  • TPH -0.21
  • IBRX 0.02
  • Stochastic Oscillator
  • TPH 17.00
  • IBRX 47.04

About TPH Tri Pointe Homes Inc.

Tri Pointe Homes Inc is an American construction company that focuses on residential construction. The company is engaged in the design, construction, and sale of single-family attached and detached homes in different states across the United States. Its operations are organized into two principal businesses: homebuilding. which generates key revenue, and financial services. The homebuilding business has three reportable operating segments, based on the geographical layout of the markets, and includes West region, Central region, and East region. The company's financial services operation is comprised of its Tri Pointe Connect mortgage financing operations, Tri Pointe Assurance title and escrow services operations, and Tri Pointe Advantage property and casualty insurance agency operations.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: